This is a feasibility study of the Nativis Voyager System in patients with recurrent glioblastoma multiforme. In this feasibility phase of the study, the first goal is to establish that the Nativis Voyager System, an investigational medical device, is safe for use in humans who have been diagnosed with re-current GBM. We will also observe the Nativis Voyager System as a potential treatment against re-current GBM and its effectiveness in slowing, shrinking or stopping the growth of recurrent GBM tumors. The effect of the electromagnetic field generated by the Voyager device has been tested in pre-clinical animal research models. Results from these preclinical studies indicate that treatment with the Nativis Voyager System may disrupt cancer cell division, thereby slowing tumor progression. Further, pre-clinical safety studies showed no safety concerns resulting from use of the Voyager device in healthy animals.<\/p>\n\n\n\n
Treatment will be given in multiple cycles. Each cycle consists of 28 days. Blood test results and MRI scan will measure how well an individual is tolerating the treatment and if the tumor is growing.<\/p>\n\n\n\n